Health Catalyst, Inc. (NASDAQ:HCAT) Shares Sold by Primecap Management Co. CA

Primecap Management Co. CA lowered its holdings in shares of Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) by 19.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,932,617 shares of the company's stock after selling 471,845 shares during the period. Primecap Management Co. CA owned about 3.18% of Health Catalyst worth $13,664,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Fred Alger Management LLC acquired a new stake in shares of Health Catalyst during the third quarter valued at $6,858,000. Millrace Asset Group Inc. acquired a new stake in shares of Health Catalyst during the 3rd quarter worth about $1,568,000. Point72 Asset Management L.P. grew its holdings in shares of Health Catalyst by 69.4% during the third quarter. Point72 Asset Management L.P. now owns 516,934 shares of the company's stock worth $4,208,000 after buying an additional 211,805 shares in the last quarter. Impax Asset Management Group plc raised its position in shares of Health Catalyst by 7.7% in the fourth quarter. Impax Asset Management Group plc now owns 2,750,000 shares of the company's stock valued at $19,442,000 after buying an additional 195,525 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Health Catalyst by 4.9% during the third quarter. Geode Capital Management LLC now owns 1,443,036 shares of the company's stock valued at $11,749,000 after buying an additional 66,896 shares during the period. Hedge funds and other institutional investors own 85.00% of the company's stock.

Remove Ads

Insider Buying and Selling at Health Catalyst

In related news, Director Duncan Gallagher sold 4,500 shares of the firm's stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $6.93, for a total value of $31,185.00. Following the sale, the director now owns 69,938 shares of the company's stock, valued at approximately $484,670.34. This trade represents a 6.05 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Daniel Lesueur sold 16,902 shares of the company's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $4.52, for a total value of $76,397.04. Following the transaction, the chief operating officer now owns 216,250 shares of the company's stock, valued at approximately $977,450. The trade was a 7.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 61,030 shares of company stock worth $330,757 over the last 90 days. Insiders own 2.50% of the company's stock.

Analysts Set New Price Targets

HCAT has been the topic of several analyst reports. KeyCorp upgraded Health Catalyst from a "sector weight" rating to an "overweight" rating and set a $9.00 price objective on the stock in a report on Wednesday, January 8th. Canaccord Genuity Group decreased their price target on Health Catalyst from $11.00 to $10.00 and set a "buy" rating on the stock in a research note on Tuesday, January 21st. Wells Fargo & Company dropped their price objective on Health Catalyst from $13.00 to $10.00 and set an "overweight" rating for the company in a report on Tuesday, January 21st. Stephens reduced their target price on Health Catalyst from $7.00 to $5.00 and set an "equal weight" rating on the stock in a report on Thursday, March 6th. Finally, Stifel Nicolaus dropped their price target on Health Catalyst from $10.00 to $5.00 and set a "hold" rating for the company in a research note on Thursday, February 27th. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, Health Catalyst currently has a consensus rating of "Moderate Buy" and an average price target of $9.27.

Health Catalyst Stock Performance

NASDAQ:HCAT traded up $0.05 during trading hours on Monday, reaching $4.46. 541,566 shares of the stock were exchanged, compared to its average volume of 601,332. Health Catalyst, Inc. has a 52 week low of $3.76 and a 52 week high of $9.24. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $313.14 million, a P/E ratio of -3.30 and a beta of 1.41. The firm has a 50 day simple moving average of $5.16 and a 200-day simple moving average of $6.96.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.